Abstract
The complex formation of K2[PdCl4] with 1-hydroxy-2-(3-pyridyl)ethylidene-diphosphonic (risedronic, Ris, H4L) acid in aqueous solutions with physiological concentration of chloride ions (0.15 mol L-1KCl) was studied using pH-potentiometry, UV-Vis and NMR 31Р spectroscopy. It was found that in the system K2[PdCl4]:Ris=1:1, equimolar complexes are formed, for which the formation constants were calculated as follows: [PdH3LCl3]2- (lgβ=39.26 (4)), [PdH2LCl3]3- (lgβ=35.66 (4)), [PdHLCl3]4- (lgβ=30.25 (6)), and [PdLCl3]5- (lgβ=22.35 (6)). The monodentate mode of coordination of risedronic acid to the central metal ion via the nitrogen atom of the pyridine ring in equimolar complexes was determined. All equimolar complexes have the chromophore composition [Pd;Namine;3Cl]. The sequential formation of complexes [PdH2LCl3]3-, [PdHLCl3]4-, and [PdLCl3]5- occurs upon deprotonation of the phosphonic groups of the ligand, which are not directly coordinated to the Pd(II) ion. Based on the constructed diagram of the equilibrium concentration distribution of complexes, it was established that in the physiological pH range, the complex [PdHLCl3]4- predominates.
The possibility of the formation the solution of complexes with coordination to Pd(II) from one to four molecules of risedronic acid, depending on the K2[PdCl4]:Ris ratio and pH values, is shown. In the systems K2[PdCl4]:Ris = 1:2, 1:3, and 1:4 at pH>5 complexes are formed in which two, three, or four molecules of risedronic acid are coordinated to Pd(II) in a monodentate mode via the nitrogen atom of the pyridine ring. These complexes have chromophores of the composition [Pd;2Namine;2Cl], [Pd;3Namine;Cl], and [Pd;4Namine], respectively. The presence of only a single signal at δ³¹P~17.3–17.8 ppm in the ³¹P NMR spectra of the K₂[PdCl₄]:Ris systems with 1:1, 1:2, 1:3, and 1:4 ratios at pH>5, along with the absence of signals corresponding to phosphonate groups directly coordinated to Pd(II) (typically observed at δ³¹P~45–30 ppm), indicates that the phosphonate groups of the ligand do not participate in the coordination sphere of Pd(II).
References
Bortolamiol E., Novaselich S., Tupini C., Fagnani S., Gambari R., Demitri N., Lampronti I., Visentin F., and Scattolin T. Palladium(II)-Imidoyl Complexes: A New Piece in the Puzzle of Organopalladium Anticancer Agents. Eur. J. Inorg. Chem. 2024. 27: e202300673. doi: 10.1002/ejic.202300673
Czarnomysy R., Radomska D., Szewczyk O. K., Roszczenko P., Bielawski K. Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments. Int. J. Mol. Sci. 2021. 22(15): 8271. doi: 10.3390/ijms22158271
Scattolin T., Voloshkin V. A., Visentin F. and Nolan S. P. A critical review of palladium organometallic anticancer agents. Cell Reports Physical Science. 2021. 2(6): 100446. doi:10.1016/j.xcrp.2021.100446
Carneiro T. J., Martins A. S., Marques M. P. M. and Gil A. M. Metabolic Aspects of Palladium(II) Potential Anti-Cancer Drugs Fron. Oncol. 2020. 10: 590970. doi: 10.3389/fonc.2020.590970
Zhang S., Gangal G., Uludag H.. ‘Magic bullets’ for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem.Soc.Rev. 2007. 36(3): 507–531. doi: 10.1039/b512310k
Livingston S.E. Chemistry of ruthenium, rhodium, palladium, osmium, iridium and platinum. Pergamon Press, 1975. P. 208.
Zekany L., Nagypal I. PSEQUAD, in: Comput. Methods Determ. Form. Constants, Springer US, Boston, MA, 1985. P 291–353.
Kozachkova A.N., Tsaryk N.V., Kostromina N.A., Pekhnyo V.I. Cis-diaminodichloropalladium(II) and hydroxyethylidenediphosphonic acid interaction. Ukr. Chem. J. 2007. 73(3): 15–19. (In Ukrainian).
Meloun M, Ferencíkova1 Z., Malkova1 H., Pekarek T. Thermodynamic dissociation constants of risedronate using spectrophotometric and potentiometric pH-titration Cent. Eur. J. Chem. 2012. 10(2): 338–353. doi.org/10.2478/s11532-011-0150-3
Bretti C., Cukrowski I., De Stefano C.and Lando G. Solubility, activity coefficients, and protonation sequence of risedronic acid. J. Chem. Eng. Data. 2014. 59(11): 3728–3740. doi: 10.1021/je500621v